OverviewSuggest Edit

Zoetis is a company engaged in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products. It offers vaccines, anti-infectives, parasiticides, other pharmaceutical products, dermatology, medicated feed additives, and animal health diagnostics for cattle, swine, poultry, fish, and sheep as well as dogs, cats, and horses.
TypePublic
Founded2012
HQParsippany-Troy Hills, NJ, US
Websitezoetis.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2019)10,600(+6%)
Job Openings282
Revenue (FY, 2020)$6.7 B(+7%)
Share Price (Jul 2021)$200.5(+2%)
Cybersecurity ratingCMore

Key People/Management at Zoetis

Kristin Peck

Kristin Peck

Chief Executive Officer and Director
Tim Bettington

Tim Bettington

Executive Vice President and President, U.S. Operations
Glenn David

Glenn David

Executive Vice President and Chief Financial Officer
Heidi Chen

Heidi Chen

Executive Vice President, General Counsel and Corporate Secretary
Rob Kelly

Rob Kelly

Executive Vice President and President, International Operations
Wetteny Joseph

Wetteny Joseph

Executive Vice President and Chief Financial Officer
Show more

Zoetis Office Locations

Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 45 other locations
Parsippany-Troy Hills, NJ, US (HQ)
10 Sylvan Way, Parsippany
DXS, AR
Virrey Loreto 2477
Wien, AT
Floridsdorfer Hauptstraße 1
Zaventem, BE
Mercuriusstraat 20
Sao Paulo, BR
Rua Luiz Fernando Rodrigues 1701
Kirkland, CA
16740 Route Transcanadienne
Show all (50)

Zoetis Financials and Metrics

Zoetis Revenue

Embed Graph
View revenue for all periods
Zoetis's revenue was reported to be $6.68 b in FY, 2020
USD

Revenue (Q1, 2021)

1.9b

Gross profit (Q1, 2021)

1.3b

Gross profit margin (Q1, 2021), %

70.7%

Net income (Q1, 2021)

558.0m

Market capitalization (22-Jul-2021)

95.2b

Closing stock price (22-Jul-2021)

200.5

Cash (31-Mar-2021)

3.6b

EV

99.0b
Zoetis's current market capitalization is $95.2 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.3b5.8b6.3b6.7b

Revenue growth, %

10%7%

Cost of goods sold

1.8b1.9b2.0b2.1b

Gross profit

3.5b3.9b4.3b4.6b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.4b1.4b1.5b1.5b1.5b1.6b1.5b1.5b1.8b1.9b

Cost of goods sold

447.0m447.0m473.0m518.0m465.0m479.0m459.0m451.0m546.0m549.0m

Gross profit

919.0m968.0m1.0b937.0m1.1b1.1b1.1b1.1b1.2b1.3b

Gross profit Margin, %

67%68%68%64%70%70%70%71%69%71%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.6b1.6b1.9b3.6b

Accounts Receivable

998.0m1.0b1.1b1.0b

Inventories

1.4b1.4b1.4b1.6b

Current Assets

4.2b4.4b4.7b6.6b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

1.7b1.6b1.3b1.7b1.8b1.8b2.0b3.4b3.7b3.6b

Accounts Receivable

943.0m973.0m929.0m970.0m994.0m1.0b965.0m984.0m1.0b1.1b

Inventories

1.4b1.4b1.4b1.4b1.4b1.4b1.5b1.6b1.6b1.7b

Current Assets

4.3b4.2b4.1b4.4b4.5b4.6b4.8b6.3b6.8b6.8b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

862.0m1.4b1.5b1.6b

Depreciation and Amortization

242.0m308.0m412.0m441.0m

Inventories

19.0m61.0m(104.0m)(346.0m)

Accounts Payable

(10.0m)37.0m(10.0m)147.0m
USDFY, 2017

Revenue/Employee

576.8k

Debt/Equity

2.8 x

Debt/Assets

0.6 x

Financial Leverage

4.8 x
Show all financial metrics

Zoetis Operating Metrics

FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020

Product Lines

300300300300300300300300300300300300

Countries

100100100100100100100100100100100100

Patents Issued

5.2 k5.5 k6 k

Trademarks

10 k10 k7.9 k
Show all operating metrics

Zoetis Acquisitions / Subsidiaries

Company NameDateDeal Size
Performance Livestock AnalyticsApril 08, 2020
Ethos Diagnostic ScienceFebruary 07, 2020
Platinum PerformanceJuly 22, 2019
AbaxisMay 15, 2018$1.9 b
NexvetApril 03, 2017$85 m
Scandinavian Micro BiodevicesAugust 08, 2016$80 m
PHARMAQNovember 02, 2015$765 m
BovigenMarch 18, 2008
Abaxis Asia Holding Limited
Abaxis Europe GmbH
Show more

Zoetis Revenue Breakdown

Embed Graph

Zoetis revenue breakdown by business segment: 7.6% from Medicated Feed Additives, 12.4% from Dermatology, 12.6% from Other Pharmaceuticals, 15.6% from Parasiticides, 20.2% from Anti-infectives, 23.9% from Vaccines and 7.6% from Other

Zoetis revenue breakdown by geographic segment: 6.0% from Other Developed Markets, 12.0% from Other Emerging Markets, 51.9% from United States and 30.2% from Other

Zoetis Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Zoetis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Zoetis Online and Social Media Presence

Embed Graph

Zoetis News and Updates

After A 10% Rise In A Month Zoetis Stock May Continue To See Higher Levels

The stock price of Zoetis, an animal health company, has seen a 10% rise over the last twenty-one trading days, while it is up 40% over the last year. ZTS stock has benefited from an increased animal adoption in the U.S., which aided its sales for parasiticide products for companion animals...

Global Veterinary Diagnostic Equipment Market Report 2021-2025 & 2030: Major Players Include IDEXX Laboratories, ABAXIS, HESKA Corporation, Zoetis and Virbac

Dublin, June 29, 2021 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostic Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The global veterinary diagnostic equipment market is expected to grow from $0.74 billion in 20…

Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?

Zoetis stock has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck’s stock has underperformed and gained only 26% of its value. Looking at valuation, Merck stock trades at about 4x trailing revenues, compared...

Global Animal Health Market (2021 to 2025) - Featuring Bayer, Eli Lilly and Zoetis Among Others

Dublin, May 25, 2021 (GLOBE NEWSWIRE) -- The "Global Animal Health Market (Feed Additives, Pharmaceuticals & Vaccines): Insights & Forecast with Potential Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.

Europe Companion Animal Diagnostics Market Set to Expand by 2020-2027 Focusing on Key Players Zoetis Inc, Randox Laboratories, Ltd., Idexx Laboratories, Inc., IDvet, Virbac

The Europe companion animal diagnostics market is to reach US$ 792.8 million by 2027 from US$ 613.6 million in 2019. The market is anticipated to grow at a CAGR of 3.8% during 2019–2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Companion Animal Diagnostics Market examined in new market research report by top companies Skyla, Randox Laboratories, IDEXX Laboratories, Zoetis

The companion animal diagnostics marketwas valued at US$ 2,031.62 million in2019 and is projected to reach US$ 2,684.86 million by 2027; it is expected to grow at a CAGR of 4.1%from 2020to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Zoetis Frequently Asked Questions

  • When was Zoetis founded?

    Zoetis was founded in 2012.

  • Who are Zoetis key executives?

    Zoetis's key executives are Kristin Peck, Tim Bettington and Glenn David.

  • How many employees does Zoetis have?

    Zoetis has 10,600 employees.

  • What is Zoetis revenue?

    Latest Zoetis annual revenue is $6.7 b.

  • What is Zoetis revenue per employee?

    Latest Zoetis revenue per employee is $629.7 k.

  • Who are Zoetis competitors?

    Competitors of Zoetis include VCA, Elanco and IDEXX Laboratories.

  • Where is Zoetis headquarters?

    Zoetis headquarters is located at 10 Sylvan Way, Parsippany, Parsippany-Troy Hills.

  • Where are Zoetis offices?

    Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 45 other locations.

  • How many offices does Zoetis have?

    Zoetis has 50 offices.